Prasugrel for patients with acute coronary syndrome undergoing balloon angioplasty
Canadian Coordinating Office for Health Technology Assessment
Record ID 32005000352
English, French
Authors' objectives:
This study aimed to review the available information on the use of prasugrel (manufactured by Eli Lilly and Company, and Sankyo Pharma) in patients with acute coronary syndrome who are to undergo percutaneous coronary intervention to open a clogged artery.
Authors' recommendations:
Given the large number of percutaneous coronary intervention procedures performed (35,000 in Canada during 2000 to 2001), any improvement in the current standard of care would influence the lives of many patients. In the future, other non-thienopyridine ADP receptor inhibitors (e.g., AR-C69931MX) and the antagonists of other platelet targets in development may influence the treatment of patients with acute coronary syndrome who are undergoing balloon angioplasty.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2005
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Angioplasty, Balloon
- Coronary Disease
- Myocardial Infarction
- Platelet Aggregation Inhibitors
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.